Genpharmasec Limited’s Board of Directors has approved the Unaudited Standalone & Consolidated Financial Results for the quarter ended June 30, 2026. The results were reviewed by the Audit Committee and subsequently approved by the Board during a meeting held on August 11, 2026. The financial statements, along with the Limited Review Reports, have been submitted to the stock exchange for record.
Genpharmasec Board Greenlights Q1 FY27 Financials
Genpharmasec Limited announced today that its Board of Directors has officially considered and approved the Unaudited Standalone & Consolidated Financial Results for the quarter that concluded on June 30, 2026. This approval follows a thorough review by the company’s Audit Committee.
Meeting Details and Outcomes
The Board meeting commenced at 03:00 p.m. on Tuesday, August 11, 2026, and concluded at 03:50 p.m. During the meeting, the Board reviewed the financial performance for the aforementioned quarter. Accompanying the financial results are the Limited Review Reports, which have also been approved and submitted.
Financial Highlights
The financial results indicate that for the quarter ended June 30, 2026, the standalone Revenue from operations stood at ₹4,478.44 Lakhs, with a Profit after tax of ₹156.96 Lakhs. On a consolidated basis, the Revenue from operations was ₹4,971.03 Lakhs, and the Profit before tax was ₹25.77 Lakhs.
The company has provided detailed segment-wise information, highlighting the performance across its various business segments, including Pharmaceuticals, Laboratory Testing, and Manufacturing & Processing.
Source: BSE
